Diagnosis
Blood tests
Suspected cases of chronic leukaemia are usually first detected after a blood test, which has often been carried to diagnose another, unrelated condition.
A blood test that reveals abnormally high levels of white blood cells could be a sign of chronic leukaemia. If you have a blood test with abnormal results, you will be referred to a haematologist (a specialist in treating blood conditions) for further testing.
Bone marrow biopsy
To confirm a diagnosis of chronic leukaemia, the haematologist will take a small sample of your bone marrow to examine under a microscope. This procedure is known as a bone marrow biopsy. A bone marrow biopsy is usually carried out under a local anaesthetic.
The haematologist will numb an area of skin at the back of your hip bone, before using a needle to remove the bone marrow sample. The procedure is usually painless although you may experience some bruising and discomfort for a few days afterwards. The procedure takes around 15 minutes to complete and you should not have to stay in hospital overnight.
The bone marrow sample will be checked to see if there are cancerous cells. If there are, the biopsy will also be able to help determine which type of chronic leukaemia is present.
Further tests
There are a number of additional tests that can be used to help reveal more information about the progress and extent of the leukaemia, which can also provide an important insight into how the leukaemia should be treated. These are outlined below.
Cytogenetic testing
Cytogenetic testing involves identifying the genetic make-up of the cancerous cells. There are a number of specific genetic variations that can occur during leukaemia and knowing what these variations are can have an important impact on treatment.
For example, 90% of people with chronic myeloid leukaemia (CML) have an altered gene, known as the Philadelphia chromosome. People who have this altered gene are known to respond well to a medicine called imatinib.
Lymph node biopsy
If you have been diagnosed with chronic leukaemia, further biopsies may be carried out on any enlarged lymph nodes that you have. These are to see how far the leukaemia has spread.
CT scans
If you have chronic leukaemia, a computerised tomography (CT) scan may be used to check that your other organs, such as your heart and lungs, are healthy.
See the A-Z topic about CT scans for more information.
^^ Back to top
Treatment
Your treatment plan
As chronic leukaemia is a complex condition, it is usually treated by a team of different healthcare specialists working together. This type of team is known as a multidisciplinary team (MDTs).
Members of your MDT may include:
- a haemato-oncologist (a specialist in the non-surgical treatment of leukaemia using techniques such as chemotherapy)
- a haemato-pathologist (a specialist in the study of cancerous blood cells)
- a pharmacist
- a social worker
- a psychologist
- a specialist cancer nurse (who will serve as the first point of contact between you and the other members of the MDT)
- a counsellor
There are several factors that will need to be taken into account when deciding on your treatment. They include:
- your age
- the extent of your cancer
- the likely progression of your cancer
- the possible side effects of treatment
No one will rush you into making a decision about your treatment, and you are free to talk to as many people as you want to, including your partner, family and friends.
Many people find that it can be helpful to write a list of questions at home to ask the MDT. Your MDT will be able to recommend what they feel are the best treatment options for you, but ultimately the decision will be yours.
The treatment of chronic leukaemia when the condition is in its early stages will depend on what type of chronic leukaemia you have. However, the treatments for both chronic myeloid leukaemia (CML) and chronic lymphocytic leukaemia in their advanced stage are more or less the same.
Early-stage chronic myeloid leukaemia (CML)
Imatinib
A medicine called imatinib is the main treatment that is recommended for CML. It is usually given as soon as a diagnosis is made because the medicine is designed to slow the progression of CML, and to prevent the condition reaching the accelerated or advanced phase.
Imatinib is a type of tyrosine kinase inhibitor. This means that it blocks a protein called tyrosine kinase (tyrosine kinase helps to stimulate the growth of cancer cells). This reduces the production of abnormal white blood cells.
Imatinib is taken orally (as a tablet). The side effects of imatinib are usually mild and should improve with time. They include:
- nausea
- vomiting
- swelling in the face and lower legs
- muscle cramps
- rash
- diarrhoea
Alternatives to imatinib
It is estimated that 10-40% of people who take imatinib become resistant to its effects, so an alternative treatment is required. Two new medications that can be used as an alternative to imatinib are:
Both medications work in a similar way to imatinib in that they block the effects of proteins that help stimulate the growth of cancer cells.
Side effects of nilotinib include:
- vomiting
- abdominal pain
- bone and joint pain
- dry skin
- loss of appetite
- hair loss
- insomnia
- night sweats
- dizziness
- tingling or numbness
Common side effects of dasatinib include:
- diarrhoea
- headache
- a rash or red, dry, itchy skin
- a build-up of fluids in the body, such as around your legs or face
- fatigue
- breathlessness
- nausea
- bone and muscle pain
If the side effects become particularly troublesome, temporarily stopping the treatment usually helps to bring them under control. Treatment can then be resumed, possibly using a lower dose of medication.
Dasatinib can also lead to a sudden drop in the number of blood cells, which means that you will become vulnerable to infection and you will bruise and bleed more easily.
See Chronic leukaemia – Complications for more information and advice about being more vulnerable to infection and bleeding.
The National Institute for Health and Clinical Excellence (NICE) has not yet made a decision about whether the NHS should provide treatment with nilotinib and dasatinib for people with chronic leukaemia.
Whether or not you will be offered dasatinib or nilotinib will be at the discretion of your Health Board. If you decide to pay for the medication privately, the cost of a 30-day course of dasatinib or nilotinib is around £2,500. Your Health Board may choose to fund some of this cost, but again, the decision is entirely at their discretion and they have no legal obligation to do so.
Alternatively, you may be offered nilotinib and dasatinib by taking part in a clinical trial. For more information about clinical trials, see below.
Clinical trials
In the UK, a number of clinical trials are underway that aim to find the best way to treat chronic leukaemia. Clinical trials are studies that use new and experimental techniques to see how well they work in treating and possibly curing chronic leukaemia.
However, you should be aware that there is no guarantee that the techniques that are being studied in the clinical trial will be more effective than current treatments.
Your care team will be able to let you know whether there are any clinical trials available in your area, as well as explaining the benefits and risks involved.
Interferon alpha
Around 30% of people with CML fail to respond to treatment to the medications that are discussed above. In this case, an alternative medication called interferon alpha may be recommended.
Interferon alpha may also be recommended if you find that the side effects of imatinib, nilotinib or dasatinib are particularly unpleasant.
Interferon alpha works by encouraging your immune system to attack the cancerous cells. It is given by injection, using a syringe. You or a relative can be trained to use the syringe so that you can have the injection at home.
The most common side effects of interferon alpha are flu-like symptoms, such as fever, chills, and muscle and joint pain. The side effects usually begin three hours after an injection and resolve after a few hours.
The side effects of interferon alpha should improve over time, but if they become troublesome, inform your MDT because additional medicines are available that can help prevent the side effects.
Less common side effects of interferon alpha include:
- nausea
- vomiting
- mood changes, such as depression
- hair loss
- dizziness
- "pins and needles" in your hands and feet
- infertility
The menstrual cycle of women who are using interferon alpha may be interrupted, and men may experience a decrease in their sperm count. For most people, infertility will be temporary, although it can be permanent in a minority of cases.
You should inform your MDT if you experience any of the less common side effects listed above because your dosage may need to be reviewed.
Treating advanced chronic myeloid leukaemia
Chemotherapy
Once chronic myeloid leukaemia has progressed to a more advanced stage, chemotherapy is the next treatment.
Chemotherapy tablets are usually used first because they have fewer and milder side effects than chemotherapy injections. Side effects include:
- tiredness
- skin rash
- increased vulnerability to infection
Chemotherapy can weaken your immune system, which helps protect you against infection. This is known as being immunocompromised. See Chronic leukaemia – Complications for more information about this.
If your symptoms persist or get worse, chemotherapy injections (intravenous chemotherapy) will need to be used. Intravenous chemotherapy causes more side effects than chemotherapy tablets and they tend to be more severe.
Side effects include:
- nausea
- vomiting
- tiredness
- hair loss
- infertility
These side effects should resolve after your treatment has finished, although there is a risk that infertility could be permanent. See Chronic leukaemia – Complications for more information about possible infertility treatments.
Rituximab
Rituximab is a new type of medication that is increasingly being used in combination with chemotherapy to treat CLL. Rituximab is what is known as a monoclonal antibody.
Monoclonal antibodies are antibodies that are genetically engineered in a laboratory. They are designed to directly target and attack cancer cells. This is why monoclonal antibody therapy can be referred to as targeted therapy.
Rituximab works by targeting a protein that is found on the surface of cancer cells, and encouraging your immune system to attack the protein which, in turn, should kill the cancer cells.
Rituximab is administered directly into your vein over the course of several hours. This is known as an infusion.
Common side effects of rituximab include:
- flu-like symptoms, such as chills and a high temperature, while the medication is being given
- dizziness
- nausea
- vomiting
In rare cases, rituximab can cause severe allergic reactions in some people. This is known as an infusion reaction and it can be fatal if left untreated.
Most infusion reactions occur within 24 hours of the first time that someone begins treatment. Therefore, it is likely that you will be closely monitored once your treatment begins. If you start to experience the symptoms of an infusion reaction, such as shortness of breath or chest pain, anti-allergy medicines, such as corticosteroids, can be used to help relieve your symptoms.
Bone marrow and stem cell transplants
The only available cure for chronic leukaemia is to have a bone marrow or stem cell transplant.
Before transplantation can take place, the person receiving the transplant has to have aggressive, high-dose chemotherapy and radiotherapy in order to destroy any cancerous cells in their body.
This can put enormous strain on the body and can cause significant side effects and potential complications. Transplantations have better outcomes if the donor has the same tissue type as the person who is receiving the donation. The best candidate to provide a donation is usually a brother or sister with the same tissue type.
Due to these issues, transplantations are usually only successful when they are carried out in children and young people, or older people in good health, and there is a suitable brother or sister who can provide a donation.
In most cases of chronic leukaemia, the potential risks of transplantation far outweigh any benefit. For example, the chances of an elderly person with advanced chronic leukaemia surviving a bone marrow transplant can be as low as one in five.
However, you may have specific individual circumstances that mean that the benefits of treatment do outweigh the risks.
See the A-Z topic about Bone marrow transplant for more on bone marrow and stem cell transplantation.
Deciding against treatment
As many of the treatments that are described in this section have unpleasant side effects that can affect your quality of life, you may decide against having a particular type of treatment.
This is entirely your decision and your MDT will respect any decision that you make. Pain relief and nursing care will be made available as and when you need it.
^^ Back to top